Hemab Therapeutics Holdings, Inc. (COAG)
Nasdaq: COAG · Biological Products, (No Diagnostic Substances) · filing with the SEC since 2026
Income statement, as filed
In thousands of US dollars (USD), as filed; per-share figures in US dollars; share counts. The fiscal year ends in December.| Fiscal quarter | Q3 FY26 | Q2 FY26 | Q1 FY26 |
|---|---|---|---|
| Period ending | Sep 30, 2026 | Jun 30, 2026 | Mar 31, 2026 |
| Report filed | Nov 10, 2026 | Aug 11, 2026 | May 21, 2026 |
| Research and development | 24,639 | 20,336 | 19,461 |
| Selling, general and administrative | 5,119 | 5,743 | 4,151 |
| Total operating expenses | 29,758 | 26,079 | 23,612 |
| Operating income | -29,758 | -26,079 | -23,612 |
| Interest and investment income | 3,384 | 2,858 | 1,219 |
| Total non-operating income (expense) | 3,147 | · | · |
| Income before income taxes | -26,611 | -24,053 | -22,675 |
| Income tax expense | 693 | 97 | 12 |
| Net income including non-controlling interests | · | · | -22,687 |
| Net income | -27,304 | -24,150 | -22,687 |
| Earnings per share, basic | -0.58 | -0.80 | -23.98 |
| Earnings per share, diluted | -0.58 | -0.80 | -23.98 |
| Weighted average shares, basic | 46,712,044 | 30,111,338 | 946,000 |
| Weighted average shares, diluted | 46,712,044 | 30,111,338 | 946,000 |
As filed with the SEC, each figure from the newest report that carries it, and linked to it. Nothing here is computed.Each quarter is three months. A fourth quarter prints only where the company tagged its three months on their own; the whole year is in the annual view.A dot is a line not tagged for that period. r restated by the company in a later report; b a share figure put on the newest basis or filed in the wrong unit. Hover a figure for its filing and note.
What each line is, and the XBRL concept behind it
Research and development spent on inventing what it sells next
us-gaap:ResearchAndDevelopmentExpenseSelling, general and administrative the cost of selling and of running the company
us-gaap:SellingGeneralAndAdministrativeExpenseTotal operating expenses the running costs together
us-gaap:OperatingExpensesOperating income profit from running the business, before interest and tax
us-gaap:OperatingIncomeLossInterest and investment income what its cash and investments earned
us-gaap:InterestIncomeOtherTotal non-operating income (expense) everything outside the business, together
us-gaap:NonoperatingIncomeExpenseIncome before income taxes profit before tax
us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterestIncome tax expense tax charged on the period's profit
us-gaap:IncomeTaxExpenseBenefitNet income including non-controlling interests the whole group's profit, minority holders' share included
us-gaap:ProfitLossNet income the profit or loss that belongs to the company's shareholders
us-gaap:NetIncomeLossEarnings per share, basic net income per share outstanding
us-gaap:EarningsPerShareBasicEarnings per share, diluted net income per share, counting every share that could be issued
us-gaap:EarningsPerShareDilutedWeighted average shares, basic the average count of shares outstanding
us-gaap:WeightedAverageNumberOfSharesOutstandingBasicWeighted average shares, diluted the average count with every share that could be issued
us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding